Institute for Translational Research in Inflammation

INFINITE | U 1286
Biology and health Research unit Precision health

Our laboratory focuses on the study of inflammation, from its origins to its consequences. We study digestive and systemic inflammatory diseases as models to evaluate the origin of inflammation, its pathophysiology, and its consequences (fibrosis and altered regeneration). We develop new drugs, therapeutic strategies and biomarkers. Each model and each project benefits from INFINITE's complementary and transversal areas of expertise (complementary medical and scientific expertise) to characterize the causes and consequences of chronic inflammation. The close relationship between INFINITE and the FHU/clinical departments ensures that scientists have access to biological resource centers and well-defined cohorts of patients with chronic inflammatory diseases. This allows for high-level translational research, which is the hallmark of INFINITE. Our program is based on scientific questions organized in four interconnected Work Packages (WPs) exploring: the origins of inflammation (environment, microbes) (WP1), mechanisms of chronic inflammation, regenerative disorders (WP2), fibrosis (WP3) and innovative therapeutic and diagnostic approaches (WP4). These Work Packages are designed to study interactions between environmental factors/microbes, epithelial cells, the mucosal barrier and the immune system, leading to the development of innovative treatments and diagnostic tools.

Informations

Director: Laurent Dubuquoy

http://lille-inflammation-research.org/fr/
https://twitter.com/LilleInfinite

1, Place de Verdun
Pôle Recherche de la Faculté de Médecine, Campus Santé, Université de Lille
59045 LILLE

Mots-clés

Inflammation, environment, nutrition, immunity, microbiology, therapeutic innovation, biomarkers, chronic inflammatory diseases, fibrosis, regenerative medicine

Localisation

  • Clinical and food bacteriology
  • Big data and deep learning
  • Functional characterization of the inflammatory status of microbial strains
  • Chemistry and Drug Design
  • Surgery
  • Effects of air and food pollutants on inflammation and gut dysbiosis
  • Environment
  • Epidemiology
  • Evaluation of antimicrobial molecules
  • Risk assessment
  • Fibrosis
  • Immunology
  • Immunotoxicology
  • Inflammation
  • Chronic inflammatory diseases
  • Microbiology
  • Intestinal microbiota
  • Microbes and intestinal homeostasis
  • Molecular modeling
  • Nutrition
  • Clinical observation and follow-up
  • Pathophysiology of epithelia
  • Digestive pathophysiology
  • Anti-inflammatory therapies

Examples of projects:

  • CPER Climibio/ECRIN
  • CPER RESIST-OMICs: Resistance and Complication in Chronic Inflammatory Diseases
  • FHU PRECISE (Precision Health in Complex Immune-Mediated Inflammatory Disease)
  • Label Team FRM 
  • ANR EVICTION
  • I-Site ULNE pilot project "Santé Environnement"
  • I-Site ULNE pilot project "Phenomix"
  • Projet HdF STIMULE "IMPULSE"
  • Projet HdF STARTAIRR "PARTICIPE: Potential of TGR5 Receptor Agonists in Colon and Intestine Inflammation: Experimental Evidence"
  • Mechanism of regulation of lactase gene expression
  • Failure of liver regeneration in the context of alcoholic hepatitis
  • Histological analysis
  • Multiplex microfluidic analysis
  • Molecular modeling
  • Tomography
  • Confocal and fluorescence imaging
  • Identification of predictive biomarkers for the onset and progression of inflammatory diseases
  • Identification of the causes of pathological inflammatory phenomena
  • Development of new experimental animal models
  • Models of experimental fibrosis
  • Analysis of the immune response
  • Preclinical evaluation of anti-inflammatory and/or antifibrotic treatments
     
  • Chemo-induced colitis models: DSS, TNBS, oxazolone
  • Enteritis models: indomethacin, piroxicam
  • Spontaneous enterocolitis model: IL10 KO mice
  • Colorectal Cancer Model (AOM-DSS)
  • Intestinal fibrosis model
  • Oral, intraperitoneal, intravenous, intrarectal, intranasal, inhalation or via alzet pumps
  • Adult, gestational, perinatal exposure
  • Acute, sub-chronic and chronic exposures

Parameters evaluated: Endoscopic scores of colitis and tumorigenesis | Histological scores of colitis, enteritis, fibrosis and dysplasia | Quantification of the inflammatory response: Cytokines/chemokines/immune populations. qRT-PCR, Elisa, Western Blot, Immunohistochemistry, Flow cytometry | Epigenetic markers | Intestinal permeability (in vivo functional tests, in vitro TEER) | Measurement of oxidative stress | Dysbiosis (metagenomic analysis by 16S sequencing) | Cytotoxicity tests, viability, cell proliferation, cell cycle, apoptosis

  • Performing antibiograms
  • Evaluation of antimicrobial molecules on a panel of reference bacterial strains (aerobic and anaerobic)
  • Determination of minimum inhibitory concentrations (MIC) of potentially bactericidal or bacteriostatic molecules, in solid and liquid media
  • Evaluation of the anti-inflammatory potential of bacterial strains (cytokine induction test on human circulating blood mononuclear cells = PBMC)
  • In vivo evaluation of the anti-inflammatory potential of bacterial strains in mouse models of experimental colitis (TNBS & DSS)

We have access to a wide range of equipment regrouped within the internal and external technological platforms:

  • Positron emission tomography (PET) imaging for small animals
  • Fluorescence microscopy imaging
  • Confocal microscopy
  • Micro-injector
  • Slide scanner
  • Molecular modeling
  • Flow cytometry
  • BSL2 laboratories

INFINITE also has a histology platform, a cell biology platform, a molecular biology platform, ...

See the full list of equipment.

Biological materials

  • Animal models (transgenic mice and rats)
  • Plasma/serum/PBMC of patients with chronic inflammatory diseases (FHU PRECISE)
  • Cell lines (Caco-2, HT29, I407, L-WRN, THP1...)
  • Primary murine and human intestinal epithelial and immune cells
  • Murine and human colonoids and enteroids

Private
CSL Behring, OctaPharma, Takeda, Boehringer-Ingelheim, Siemens Healthineers
Société Lesaffre (Bourse CIFRE en cours 2021-2024)

Academic
Institut Cochin, Paris, Institut Mondor de recherche biomedicale, Créteil, LPCA, ULCO, ULCO, ANSES, UMR 454 MEDIS, UMR 1241, Inserm, Université de Rennes 1, UMR1137, Paris, UMR1071, Université de Clermont Auvergne
University of Perugia (Italy), University of Oslo (Norway), University of Zurich (Switzerland), Leeds (UK), Royal Free Hospital London (UK)

Back